Sunmax Biotechnology Co Ltd (4728) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sunmax Biotechnology Co Ltd (4728) has a cash flow conversion efficiency ratio of 0.111x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$160.84 Million ≈ $5.07 Million USD) by net assets (NT$1.44 Billion ≈ $45.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4728 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Sunmax Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Sunmax Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sunmax Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunmax Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PYC Therapeutics Ltd
AU:PYC
|
-0.203x |
|
Vestum AB (publ)
ST:VESTUM
|
0.014x |
|
Tianjin Lisheng Pharmaceutical Co Ltd
SHE:002393
|
0.062x |
|
Cikarang Listrindo Tbk PT
JK:POWR
|
0.074x |
|
Sichuan Mingxing Electric Power Co Ltd
SHG:600101
|
0.044x |
|
PIMCO Access Income Fund
NYSE:PAXS
|
N/A |
|
DCB Bank Limited
NSE:DCBBANK
|
-0.040x |
|
Ichia Technologies Inc
TW:2402
|
0.044x |
Annual Cash Flow Conversion Efficiency for Sunmax Biotechnology Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Sunmax Biotechnology Co Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Sunmax Biotechnology Co Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.51 Billion ≈ $47.66 Million |
NT$397.37 Million ≈ $12.52 Million |
0.263x | -55.86% |
| 2023-12-31 | NT$1.43 Billion ≈ $44.93 Million |
NT$848.56 Million ≈ $26.73 Million |
0.595x | +129.93% |
| 2022-12-31 | NT$1.33 Billion ≈ $41.75 Million |
NT$342.97 Million ≈ $10.81 Million |
0.259x | +8.88% |
| 2021-12-31 | NT$1.02 Billion ≈ $32.25 Million |
NT$243.28 Million ≈ $7.66 Million |
0.238x | -45.41% |
| 2020-12-31 | NT$888.84 Million ≈ $28.00 Million |
NT$386.97 Million ≈ $12.19 Million |
0.435x | +1.78% |
| 2019-12-31 | NT$676.83 Million ≈ $21.32 Million |
NT$289.51 Million ≈ $9.12 Million |
0.428x | +174.90% |
| 2018-12-31 | NT$648.01 Million ≈ $20.42 Million |
NT$100.83 Million ≈ $3.18 Million |
0.156x | +140.26% |
| 2017-12-31 | NT$572.70 Million ≈ $18.04 Million |
NT$37.09 Million ≈ $1.17 Million |
0.065x | +116.86% |
| 2016-12-31 | NT$555.29 Million ≈ $17.49 Million |
NT$16.58 Million ≈ $522.46K |
0.030x | +172.98% |
| 2015-12-31 | NT$558.24 Million ≈ $17.59 Million |
NT$-22.84 Million ≈ $-719.74K |
-0.041x | -- |
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.